Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Journal of Psychopharmacology (Oxford, England)|May 10, 2014
Restoration of positive mood states in major depression as a potential drug development targetRoger M LaneJournal of Psychopharmacology (Oxford, England)|October 16, 2014
Antidepressant drug development: Focus on triple monoamine reuptake inhibitionRoger M LaneMedical Hypotheses|April 11, 2009
Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementiasRoger M Lane, Yunsheng HeAlzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 10, 2012
Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotypeRoger M Lane, Yunsheng HeJournal of Lipid Research|February 18, 2005
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's diseaseRoger M Lane, Martin R FarlowJournal of Alzheimer'S Disease : JAD|November 20, 2014
Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic valueRoger M Lane, Taher Darreh-ShoriThe International Journal of Neuropsychopharmacology|August 9, 2005
Targeting acetylcholinesterase and butyrylcholinesterase in dementiaRoger M Lane, Steven G Potkin, Albert EnzJournal of Alzheimer'S Disease : JAD|July 28, 2007
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differencesMurat Emre, Jeffrey L Cummings, Roger M LaneClinical Neuropharmacology|June 11, 2004
Acetylcholinesterase and its inhibition in Alzheimer diseaseRoger M Lane, Miia Kivipelto, Nigel H GreigMovement Disorders : Official Journal of the Movement Disorder Society|June 27, 2008
Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patientsPaolo Barone, David J Burn, Teus van Laar, et al.Pageof 2